As Arg-1 expression of TAMs was previously shown to be a central driver of immunosuppression in pancreatic cancer by inhibiting CD8+ T cell recruitment,59 this modulation is in agreement with increased immune cell activity, most prominently the increased frequencies of cytotoxic CD8+ T cells, and superior efficacy in the BETi+SMACm cohort. The gene discussed is CD8A; the disease is pancreatic neoplasm.